Pharmacogenomics and Personalized Medicine (Aug 2019)

A personalized approach to acute myeloid leukemia therapy: current options

  • Illangeswaran RSS,
  • Das S,
  • Paul DZ,
  • Mathews V,
  • Balasubramanian P

Journal volume & issue
Vol. Volume 12
pp. 167 – 179

Abstract

Read online

Raveen Stephen Stallon Illangeswaran, Saswati Das, Daniel Zechariah Paul, Vikram Mathews, Poonkuzhali BalasubramanianDepartment of Haematology, Christian Medical College, Vellore, IndiaAbstract: Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.Keywords: acute myeloid leukemia, personalized medicine, chemotherapy, molecular markers

Keywords